Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time ...

This study presents a useful reassessment of the potential role of dendritic cell-derived IL-27 p28 cytokine in the functional maturation of CD4+CD8- thymocytes, and CD4+ recent thymic emigrants. The ...

Combining SBRT with GM-CSF and peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors: A single arm, single center, phase II trial.

Association of immune-related adverse events with survival and treatment outcomes in thymic tumors treated with immune checkpoint inhibitors. Comparing impact of treatment before or after surgery in ...

Zhang et al. demonstrate that CD4+ single positive (SP) thymocytes, CD4+ recent thymic emigrants (RTE), and CD4+ T naive (Tn) cells from Cd11c-p28-flox mice, which lack IL-27p28 selectively in Cd11c+ ...

Data from the WAYFINDER study showed clinically meaningful reductions and discontinuations of oral corticosteroids.

Chugai files regulatory application with Japanese MHLW for additional indication of Tecentriq to treat thymic carcinoma: Tokyo Tuesday, May 20, 2025, 15:00 Hrs [IST] Chugai Pharma ...

A panelist discusses how NCCN guidelines now include cabozantinib as a category 1 recommendation for gastrointestinal (GI) ...

BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseasesBD9 designed ...

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced the initiation of a Phase 2 trial for its investigational drug bosakitug (ATI-045), targeting moderate-to-severe atopic dermatitis ...

Background Minimally invasive approaches, including video-assisted thoracoscopic thymectomy (VATT) and robot-assisted thoracoscopic thymectomy (RATT), have emerged as alternatives to median sternotomy ...